SIGA Technologies : Summary ToggleSIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017
September 20, 2017 at 07:45 am EDT
Share
NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that Dr. Phillip L. Gomez, SIGA's Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference in New York City at 8:00 am ET on Wednesday, September 27, 2017. Dr. Gomez will provide a corporate update and discuss the company's lead investigational product TPOXX, an antiviral drug targeting the treatment of orthopoxvirus infections, including smallpox.
To access the live webcast and a copy of the presentation starting that morning, please visit the Investor Relations section of the Company's website, under Events & Presentations, or click here. A replay will be available for a limited time following the presentation.
ABOUT SIGA TECHNOLOGIES, INC.
SIGA Technologies, Inc. is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company's lead product is tecovirimat, TPOXX, also known as ST-246, an orally administered and IV formulation antiviral drug that targets orthopoxvirus infections, including smallpox. While TPOXX is not yet approved as safe and effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield. For more information about SIGA, please visit www.siga.com.
FORWARD-LOOKING STATEMENTS
This press release contains certain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to the submission and approval of TPOXXby the U.S. Food & Drug Administration. Such forward-looking statements are subject to various known and unknown risks and uncertainties and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA's actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA's control. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.
SIGA Technologies Inc. published this content on 20 September 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 20 September 2017 11:44:10 UTC.
Original documenthttps://investor.siga.com/news-releases/news-release-details/siga-present-cantor-fitzgerald-global-healthcare-conference
Public permalinkhttp://www.publicnow.com/view/3549E5E802815304B5CE57BF2431D0373FF16A92
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.